Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;118:1651-1658
Published online before print September 29, 2008, doi: 10.1161/CIRCULATIONAHA.107.758623
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
118/16/1651    most recent
CIRCULATIONAHA.107.758623v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szokodi, I.
Right arrow Articles by Ruskoaho, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szokodi, I.
Right arrow Articles by Ruskoaho, H.
Related Collections
Right arrow Contractile function
Right arrow Cell signalling/signal transduction
Right arrowRelated Article

(Circulation. 2008;118:1651-1658.)
© 2008 American Heart Association, Inc.


Molecular Cardiology

Functionally Opposing Roles of Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase in the Regulation of Cardiac Contractility

István Szokodi, MD, PhD*; Risto Kerkelä, MD, PhD*; Anna-Maria Kubin, MD; Balázs Sármán, MD, PhD; Sampsa Pikkarainen, MD, PhD; Attila Kónyi, MD; Iván G. Horváth, MD, PhD; Lajos Papp, MD, PhD; Miklós Tóth, MD, PhD; Réka Skoumal, PhD; Heikki Ruskoaho, MD, PhD

From the Institute of Biomedicine, Department of Pharmacology and Toxicology, Biocenter Oulu, University of Oulu, Oulu, Finland (I.S., R.K., A.-M.K., S.P., R.S., H.R.); Heart Institute, Medical School, University of Pécs, Pécs, Hungary (I.S., A.K., I.G.H., L.P.); Center for Translational Medicine, Jefferson Medical College, Philadelphia, Pa (R.K.); and Szentágothai János Knowledge Centre, Budapest, Hungary (B.S., M.T., R.S.).

Correspondence to Heikki Ruskoaho, MD, PhD, Institute of Biomedicine, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Oulu, PO Box 5000, 90014 University of Oulu, Finland. E-mail heikki.ruskoaho{at}oulu.fi

Received March 12, 2006; accepted August 4, 2008.

Background— Extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase (p38-MAPK) have been shown to regulate various cellular processes, including cell growth, proliferation, and apoptosis in the heart. However, the function of these signaling pathways in the control of cardiac contractility is unclear. Here, we characterized the contribution of ERK1/2 and p38-MAPK to the inotropic effect of endothelin-1 (ET-1).

Methods and Results— In isolated perfused rat hearts, infusion of ET-1 (1 nmol/L) for 10 minutes increased contractility and phosphorylation of ERK1/2 and their downstream target p90 ribosomal S6 kinase (p90RSK). Suppression of ERK1/2 activation prevented p90RSK phosphorylation and attenuated the inotropic effect of ET-1. Pharmacological inhibition of epidermal growth factor receptor kinase activity abolished ET-1–induced epidermal growth factor receptor transactivation and ERK1/2 and p90RSK phosphorylation and reduced ET-1–mediated inotropic response. Moreover, inhibition of the p90RSK target Na+-H+ exchanger 1 attenuated the inotropic effect of ET-1. In contrast to ERK1/2 signaling, suppression of p38-MAPK activity further augmented ET-1–enhanced contractility, which was accompanied by increased phosphorylation of phospholamban at Ser-16.

Conclusions— MAPKs play opposing roles in the regulation of cardiac contractility in that the ERK1/2-mediated positive inotropic response to ET-1 is counterbalanced by simultaneous activation of p38-MAPK. Hence, selective activation of ERK1/2 signaling and inhibition of p38-MAPK signaling may represent novel means to support cardiac function in disease.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 118: 1605-1606. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Cardiovasc ResHome page
E. Calderon-Sanchez, C. Delgado, G. Ruiz-Hurtado, A. Dominguez-Rodriguez, V. Cachofeiro, M. Rodriguez-Moyano, A. M. Gomez, A. Ordonez, and T. Smani
Urocortin induces positive inotropic effect in rat heart
Cardiovasc Res, September 1, 2009; 83(4): 717 - 725.
[Abstract] [Full Text] [PDF]